Fatty acid synthesis in the fetal lung: relationship to surfactant lipids.
The aims of this study were to investigate the control of fatty acid synthesis and its relationship to surfactant production in the fetal lung during alteration of hormonal and substrate conditions. Lung explants from 18 day fetuses (term = 22 days) which were cultured 2 days in the presence of 10 mM lactate showed parallel acceleration of de novo fatty acid synthesis (3H2O incorporation) and [14C]choline incorporation into disaturated phosphatidylcholine (DSPC) compared to culture of explants in glucose. Both the cultured and fresh explants were resistant to the classical short term (4 h) cAMP inhibition of fatty acid synthesis with 3 mM dibutyryl cAMP or 0.5 mM aminophylline. In the cultured explants short term cAMP elevation increased DSPC production, and long term (2 day) cAMP elevation caused a further increase in DSPC synthesis and also stimulated fatty acid synthesis. In cultured explants from 17 day fetuses, dexamethasone (0.1 microM) caused a synergistic increase with aminophylline in both fatty acid synthesis and DSPC production whereas, in explants from 18 day fetuses, dexamethasone inhibited both processes and reduced the level of stimulation of DSPC and fatty acid synthesis seen with aminophylline alone. Dexamethasone also reduced the stimulation of both DSPC and fatty acid synthesis produced in the culture of 18 day explants with bacitracin (0.5 mg/ml), whereas the combination of bacitracin and aminophylline resulted in a synergistic increase in DSPC production. Culture with glucagon (0.1 microM) also stimulated DSPC synthesis but at physiological levels insulin had no effect on either DSPC or fatty acid synthesis. These data show that lung fatty acid synthesis exhibits unique features of fatty acid synthesis regulation compared to other lipogenic tissues and also suggest a link between de novo fatty acid synthesis and surfactant production during the critical period of accelerated lung maturation.
D000628:Aminophylline / Q000494:pharmacology; D000818:Animals; D001414:Bacitracin / Q000494:pharmacology; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000494:pharmacology; D004247:DNA / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D005227:Fatty Acids / Q000096:biosynthesis*; D005260:Female; D005865:Gestational Age; D007328:Insulin / Q000494:pharmacology; D007773:Lactates / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000196:embryology* / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D011663:Pulmonary Surfactants / Q000096:biosynthesis / Q000378:metabolism*; D051381:Rats
D005227:Fatty Acids; D007328:Insulin; D007773:Lactates; D010743:Phospholipids; D011506:Proteins; D011663:Pulmonary Surfactants; D001414:Bacitracin; D000628:Aminophylline; D003907:Dexamethasone; D004247:DNA; D000242:Cyclic AMP